TACC3 and gallbladder cancer: In this review, we also report a patient with gallbladder cancer with FGF3-TACC3 fusion gene with negative HER2/neu gene amplification on NGS (confirmed by IHC and FISH, both being negative) who was treated with targeted FGFR inhibitors (dovitinib followed by pazopanib) resulting in initial response.